Consumer marketers feeling more confident, says survey

Share this article:
The economy might be retrenching and consumers souring, but consumer marketers are feeling more confident, according to a survey by Cegedim Dendrite which found that four in 10 expect DTC spend to increase in 2010.

Nearly three-quarters of those surveyed said spending would hold steady or increase, a big jump over last year's 43%, with 41% anticipating increased spending.
Of that 41% nearly half said the increase will come from more funds allocated to direct-to-patient (DTP) programs.

Among those anticipating decreased spending, half said funds would be shifted to different programs, 19% cited a shift to targeted DTP, 16% predicted a shift to professional promotion, 10% said funds would shift to more persistence and adherence programs and 9% anticipated a shift to more integrated non-personal promotion.

Respondents said TV, direct mail and radio budgets should be cut and the savings shifted into other areas. Asked where they'd like to see more spent, 72% said relationship marketing, while only 58% said they expected to see that happen, while 73% said loyalty card and persistence programming, with only 55% expecting increased spending in those areas.

Spending was expected to stay the same for awareness and trial, while leaping 48% on usage, indicating a shift away from spending to generate new customers and towards low-cost customer retention, said Cegedim Dendrite.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.